Key result
Semaglutide eligibility expands across current indications to encompass over half of US adults.
This study estimates the population-level eligibility for semaglutide among US adults across all its current indications.
This cross-sectional study uses National Health and Nutrition Examination Survey data to examine the number of US adults eligible for semaglutide across all current indications.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2024) studied this question. Semaglutide eligibility across all current indications was quantified for US adults using National Health and Nutrition Examination Survey data.
Synapse has enriched 5 related papers. Consider them for comparative context: